Fernandez Nicolas, Chua Michael E, Ming Jessica M, Silangcruz Jan Michael, Zu'bi Fadi, Dos Santos Joana, Lorenzo Armando J, Braga Luis H, Lopes Roberto Iglesias
Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada.
Division of Pediatric Urology, The Hospital for Sick Children, Toronto, Canada.
Urology. 2017 Dec;110:201-207. doi: 10.1016/j.urology.2017.08.003. Epub 2017 Aug 17.
To assess the efficacy and safety of neurostimulation for non-neurogenic overactive bladder in children, we conducted a meta-analysis of randomized controlled trials (RCTs).
A systematic literature search was performed on August 2016. RCTs were evaluated according to the Cochrane Collaboration risk of bias assessment. Number of patients with post-treatment partial response (PR) (50%-89%), complete response (CR) (≥90%), and full response (FR) (100%) were extracted for relative risk (RR) and 95% confidence interval (CI). Effect estimates were pooled using the Mantel-Haenszel method with random effect model if significant inter-study heterogeneity (P <.1) was noted. Subgroup analysis was performed according to each treatment setting (PROSPERO CRD42016043502).
Five eligible studies (245 patients) were included. Overall effect estimates showed that compared with standard urotherapy, neurostimulation demonstrated significantly better ≥50% (PR + CR + FR) response (RR = 2.8, 95% CI 1.1-7.2), but not ≥90% (CR + FR) response (RR = 8.28, 95% CI 0.65-105.92). Clinic-based neurostimulation had significantly better treatment outcomes for both ≥50% (PR + CR + FR) and ≥90% (CR + FR) responses (RR = 3.24, 95% CI 1.89-5.57; RR = 20.81, 95% CI 2.97-145.59, respectively), whereas a self-administered regimen showed no differences for both ≥50% (PR + CR + FR) and ≥90% (CR + FR) response rates between treatment groups (RR = 2.61, 95% CI 0.48-14.15; RR = 3.55, 95% CI 0.19-67.82, respectively). No serious adverse events were reported.
Neurostimulation therapy may lead to better partial improvement of non-neurogenic overactive bladder; however, it may not render a definitive complete response. Office-based neurostimulation seems more efficacious than self-administered neurostimulation. Further RCTs are needed to compare outcomes of the 2 regimens.
为评估神经刺激疗法对儿童非神经源性膀胱过度活动症的疗效和安全性,我们开展了一项随机对照试验(RCT)的荟萃分析。
于2016年8月进行了系统的文献检索。根据Cochrane协作网偏倚风险评估对RCT进行评价。提取治疗后部分缓解(PR)(50%-89%)、完全缓解(CR)(≥90%)和完全反应(FR)(100%)的患者数量,用于计算相对危险度(RR)和95%置信区间(CI)。如果研究间存在显著异质性(P <0.1),则采用随机效应模型的Mantel-Haenszel法合并效应估计值。根据每种治疗方案进行亚组分析(国际前瞻性系统评价注册库CRD42016043502)。
纳入了5项符合条件的研究(245例患者)。总体效应估计显示,与标准尿疗法相比,神经刺激疗法在≥50%(PR+CR+FR)反应方面显著更好(RR=2.8,95%CI 1.1-7.2),但在≥90%(CR+FR)反应方面并非如此(RR=8.28,95%CI 0.65-105.92)。基于门诊的神经刺激疗法在≥50%(PR+CR+FR)和≥90%(CR+FR)反应方面的治疗效果均显著更好(RR分别为3.24,95%CI 1.89-5.57;RR为20.81,95%CI 2.97-145.59),而自我给药方案在治疗组间≥50%(PR+CR+FR)和≥90%(CR+FR)反应率方面均无差异(RR分别为2.61,95%CI 0.48-14.15;RR为3.55,95%CI 0.19-67.82)。未报告严重不良事件。
神经刺激疗法可能会使非神经源性膀胱过度活动症有更好的部分改善;然而,它可能无法带来明确的完全缓解。基于门诊的神经刺激疗法似乎比自我给药的神经刺激疗法更有效。需要进一步的RCT来比较这两种方案的结果。